Hospitalization as an outcome in ambulatory COVID-19 trials-not applicable in every setting

Clin Microbiol Infect. 2022 Sep;28(9):1187-1188. doi: 10.1016/j.cmi.2022.05.026. Epub 2022 May 30.

Authors

Isaac Núñez¹, Sergio Iván Valdés-Ferrer², Adrian Soto-Mota³

Affiliations

¹ Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address: isaac.nunezs@incmnsz.mx.
² Department of Neurology & Psichiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
³ Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

No abstract available

Keywords: COVID-19; Clinical trials; Molnupiravir; Nirmatrelvir; Remdesivir; SARS-CoV-2.

MeSH terms

Adenosine Monophosphate
Antiviral Agents / therapeutic use
COVID-19*
Hospitalization
Humans
SARS-CoV-2

Substances

Antiviral Agents
Adenosine Monophosphate